Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170149 | 1.00 | CA1 (0.39) | CA1CA2CA7CA9SMPD1 | |
| Choline SCHEMBL16267506 | 0.87 | MEN1 (0.32) | CA1CA2CA7 | |
| SCHEMBL8722298 | 0.86 | CA1 (0.37) | CA1CA2CA7CA9 | |
| SCHEMBL28412357 | 0.84 | CA1 (0.38) | CA1CA2CA7CA9 | |
| SCHEMBL958656 | 0.84 | LPAR3 (0.40) | CA1CA2CA7CA9LPAR2 | |
| SCHEMBL8015659 | 0.83 | CA1 (0.35) | CA1CA2CA7CA9 | |
| SCHEMBL7833013 | 0.83 | CA1 (0.33) | CA1CA2CA7CA9 | |
| SCHEMBL958655 | 0.83 | CA1 (0.37) | CA1CA2CA7CA9 | |
| SCHEMBL15290149 | 0.81 | CA1 (0.36) | CA1CA2CA7CA9SMPD1 | |
| SCHEMBL28066491 | 0.81 | CA1 (0.36) | CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0674529-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | NeXstar Pharmaceuticals, Inc. (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1994013324-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | VESTAR, INC. (US) | 1994-06-23 | — | — | WO | claimed |
| EP-2850070-B1 | BENZO[1,3]DIOXINE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS | SANOFI SA (FR) | 2017-08-23 | — | — | EP | disclosed |
| EP-2850062-B1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH PATHOLOGICAL THROMBUS FORMATION | SANOFI SA (FR) | 2017-07-19 | — | — | EP | disclosed |
| US-9346762-B2 | Pyrazole derivatives and their use as LPAR5 antagonists | SANOFI (FR) | 2016-05-24 | — | — | US | disclosed |
| US-9346757-B2 | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation | SANOFI (FR) | 2016-05-24 | — | — | US | disclosed |
| US-9221784-B2 | Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists | SANOFI (FR) | 2015-12-29 | — | — | US | disclosed |
| US-20150141477-A1 | Pyrazole Derivatives And Their Use As LPAR5 Antagonists | SANOFI (FR) | 2015-05-21 | — | — | US | disclosed |
| US-20150141471-A1 | Pyridine Derivatives And Their Use In The Treatment Of Conditions Associated With Pathological Thrombus Formation | SANOFI (FR) | 2015-05-21 | — | — | US | disclosed |
| US-20150111889-A1 | Benzo[1,3]Dioxine Derivatives And Their Use As LPAR5 Antagonists | SANOFI (FR) | 2015-04-23 | — | — | US | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| EP-0837630-A4 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | UNIV CALIFORNIA (US) | 1998-11-25 | — | — | EP | disclosed |
| US-5827831-A | Lipid nucleotide analog prodrugs for oral administration | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-10-27 | — | — | US | disclosed |
| EP-0837630-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-29 | — | — | EP | disclosed |
| US-5744592-A | IMPROVING THE BIOAVAILABILITY AND ABSORPTION OF A DRUG THROUGH THE DIGESTIVE TRACT BY COVALENTLY BONDING THE DRUG AND A 1-O-OR-S-ALKYL-SN-GLYCERO-3-PHOSPHATE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-04-28 | — | — | US | disclosed |
| WO-1996039831-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5484809-A | ANTITUMOR | VESTAR, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0674529-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | NeXstar Pharmaceuticals, Inc. (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5411947-A | converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives; drugs such as AZT, cladribine, AICA-Riboside | VESTAR, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| WO-1994013324-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | VESTAR, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141471-A1 | Pyridine Derivatives And Their Use In The Treatment Of Conditions Associated With Pathological Thrombus Formation | LPAR5, LPAR1, LPAR3 | CA1 3002/4885CA2 1939/4885CA7 4105/4885 |
| US-20150111889-A1 | Benzo[1,3]Dioxine Derivatives And Their Use As LPAR5 Antagonists | LPAR5, LPAR1, LPAR2 | CA1 3351/4885CA2 2288/4885CA7 4086/4885 |
| US-20150141477-A1 | Pyrazole Derivatives And Their Use As LPAR5 Antagonists | LPAR5, LPAR3, LPAR1 | CA1 3067/4885CA2 2172/4885CA7 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.